Detalhe da pesquisa
1.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Lancet Oncol
; 24(9): 1029-1041, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657462
2.
Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool.
Biol Res
; 56(1): 63, 2023 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38041132
3.
Long Non-Coding RNAs (lncRNAs) as Regulators of the PI3K/AKT/mTOR Pathway in Gastric Carcinoma.
Int J Mol Sci
; 24(7)2023 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37047267
4.
A Single Variant in Pri-miRNA-155 Associated with Susceptibility to Hereditary Breast Cancer Promotes Aggressiveness in Breast Cancer Cells.
Int J Mol Sci
; 23(23)2022 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36499743
5.
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
Future Oncol
; 11(3): 421-9, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25675123
6.
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape.
NPJ Breast Cancer
; 10(1): 15, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388477
7.
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.
Cancer Chemother Pharmacol
; 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38305868
8.
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
J Clin Oncol
; : JCO2301500, 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38537155
9.
The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application.
Diagnostics (Basel)
; 13(19)2023 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37835815
10.
Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer.
Cancer Res Commun
; 3(12): 2551-2559, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38019116
11.
Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug-induced heart rate changes.
Clin Transl Sci
; 16(5): 823-834, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36772881
12.
Environmental and Lifestyle Risk Factors in the Carcinogenesis of Gallbladder Cancer.
J Pers Med
; 12(2)2022 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35207722
13.
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer.
Expert Opin Investig Drugs
; 31(6): 515-529, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34694932
14.
Role of lncRNAs in the Development of an Aggressive Phenotype in Gallbladder Cancer.
J Clin Med
; 10(18)2021 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34575316
15.
The Emerging Role of PIWI-Interacting RNAs (piRNAs) in Gastrointestinal Cancers: An Updated Perspective.
Cancers (Basel)
; 14(1)2021 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35008366
16.
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
J Immunother Cancer
; 9(3)2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33737339
17.
Endothelin-converting enzyme-1c promotes stem cell traits and aggressiveness in colorectal cancer cells.
Mol Oncol
; 14(2): 347-362, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31788944
18.
Phosphorylation of Endothelin-Converting Enzyme-1c at Serines 18 and 20 by CK2 Promotes Aggressiveness Traits in Colorectal Cancer Cells.
Front Oncol
; 10: 1004, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32850305
19.
Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis.
Thromb Haemost
; 99(6): 1104-11, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18521515
20.
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
Lung Cancer
; 98: 1-8, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27393499